Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research report issued on Wednesday, MarketBeat Ratings reports. They presently have a $16.50 price target on the biopharmaceutical company’s stock, down from their prior price target of $17.50. Chardan Capital’s target price suggests a potential upside of 22.22% from the stock’s current price.

FOLD has been the topic of a number of other reports. J P Morgan Chase & Co set a $13.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a research note on Monday, June 5th. Bank of America Corporation reduced their price target on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Cowen and Company restated a “buy” rating and issued a $16.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 16th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.75.

Shares of Amicus Therapeutics (FOLD) traded down 0.44% during trading on Wednesday, hitting $13.46. 2,338,367 shares of the company’s stock were exchanged. The stock’s market cap is $2.22 billion. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $14.36. The stock’s 50-day moving average price is $13.20 and its 200-day moving average price is $9.66.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the prior year, the company posted ($0.40) earnings per share. On average, equities analysts expect that Amicus Therapeutics will post ($1.37) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics’ (FOLD) “Buy” Rating Reaffirmed at Chardan Capital” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/amicus-therapeutics-inc-fold-price-target-cut-to-16-50-by-analysts-at-chardan-capital.html.

In other news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the stock in a transaction on Thursday, July 13th. The stock was purchased at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jay Barth sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $10.00, for a total transaction of $300,000.00. Following the transaction, the insider now owns 64,184 shares of the company’s stock, valued at approximately $641,840. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in FOLD. Teacher Retirement System of Texas raised its holdings in Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares during the last quarter. Princeton Alpha Management LP bought a new position in Amicus Therapeutics during the 1st quarter worth approximately $106,000. DORCHESTER WEALTH MANAGEMENT Co bought a new position in Amicus Therapeutics during the 2nd quarter worth approximately $111,000. Tudor Investment Corp ET AL bought a new position in Amicus Therapeutics during the 2nd quarter worth approximately $124,000. Finally, Aperio Group LLC raised its holdings in Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,663 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.